Literature DB >> 2517125

Impaired T-cell activation in patients with systemic lupus erythematosus.

S Sierakowski1, E J Kucharz, R W Lightfoot, J S Goodwin.   

Abstract

Interleukin-2 (IL-2) production was studied in T lymphocytes from 32 patients with systemic lupus erythematosus (SLE) and 27 healthy volunteers. The IL-2 production by phytohemagglutinin (PHA)-stimulated cells from SLE patients was significantly depressed compared to control values, with a correlation between degree of depression and disease activity. The depressed IL-2 production by SLE T cells are largely reversed by the addition of either phorbol ester (PMA) or partially by a calcium ionophore. SLE T cells had significantly lower peak increases in intracellular free calcium [( Ca2+]i) than controls after stimulation by PHA or by a monoclonal antibody against the CD3 antigen. This abnormality was found even in T cells from patients with mild disease activity or in those whose T cells produced normal amounts of IL-2. Calcium ionophore produced similar increases in [Ca2+]i in SLE patients as in normals. These results suggest that a major component of the defect responsible for decreased IL-2 production by SLE lymphocytes is proximal to protein kinase C activation and may involve impaired signal transduction after activation of the antigen receptor complex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517125     DOI: 10.1007/bf00918016

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

1.  Abnormalities of delayed hypersensitivity in systemic lupus erythematosus.

Authors:  B H Hahn; K K Bagby; C K Osterland
Journal:  Am J Med       Date:  1973-07       Impact factor: 4.965

2.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

Authors:  J P Van Wauwe; J R De Mey; J G Goossens
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

3.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

4.  Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N Miyasaka; T Nakamura; I J Russell; N Talal
Journal:  Clin Immunol Immunopathol       Date:  1984-04

5.  Lymphokines in autoimmunity: relationship between interleukin-2 and interferon-gamma production in systemic lupus erythematosus.

Authors:  W L Sibbitt; C Kenny; C W Spellman; K D Ley; A D Bankhurst
Journal:  Clin Immunol Immunopathol       Date:  1984-08

6.  Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator.

Authors:  R Y Tsien; T Pozzan; T J Rink
Journal:  J Cell Biol       Date:  1982-08       Impact factor: 10.539

7.  Clonal diversity and T-cell receptor beta-chain variable gene expression in enlarged lymph nodes of MRL-lpr/lpr lupus mice.

Authors:  P A Singer; R J McEvilly; D J Noonan; F J Dixon; A N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  The lymphoproliferating cells of MRL-lpr/lpr mice are a polyclonal population that bear the T lymphocyte receptor for antigen.

Authors:  D A Nemazee; S Studer; M Steinmetz; Z Dembić; M Kiefer
Journal:  Eur J Immunol       Date:  1985-08       Impact factor: 5.532

9.  Impaired T cell capping and receptor regeneration in active systemic lupus erythematosus. Evidence for a disorder intrinsic to the T lymphocyte.

Authors:  G M Kammer
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

10.  Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus.

Authors:  Y Murakawa; S Takada; Y Ueda; N Suzuki; T Hoshino; T Sakane
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

View more
  8 in total

1.  Chronic administration of dexamethasone results in Fc receptor up-regulation and inhibition of class I antigen expression on macrophages from MRL/lpr autoimmune mice.

Authors:  S H Zuckerman; G F Evans; N Bryan
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

Review 2.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

Review 3.  Therapeutic potential of protein kinase C inhibitors.

Authors:  D Bradshaw; C H Hill; J S Nixon; S E Wilkinson
Journal:  Agents Actions       Date:  1993-01

4.  Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus.

Authors:  Stella A Nicolaou; Lisa Neumeier; Koichi Takimoto; Susan Molleran Lee; Heather J Duncan; Shashi K Kant; Anne Barbara Mongey; Alexandra H Filipovich; Laura Conforti
Journal:  Cell Calcium       Date:  2009-12-02       Impact factor: 6.817

5.  Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus.

Authors:  Keiko Yoshimoto; Yumiko Setoyama; Kensei Tsuzaka; Tohru Abe; Tsutomu Takeuchi
Journal:  J Biomed Biotechnol       Date:  2010-09-06

6.  Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.

Authors:  M Pang; Y Setoyama; K Tsuzaka; K Yoshimoto; K Amano; T Abe; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

7.  Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE).

Authors:  K Mitamura; H Kang; Y Tomita; H Hashimoto; S Sawada; T Horie
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

8.  Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW)F1 mice: analysis of T-cell lymphokine synthesis.

Authors:  M N Sato; P Minoprio; S Avrameas; T Ternynck
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.